Lisata Therapeutics, Inc.
LSTA
Rank in Stocks
#28712
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Share Price
$1.12
Last synced: 2026-11-09
Market Cap
$10.09M
Change (1 day)
8.74%
Change (1 year)
-48.15%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lisata Therapeutics, Inc. (LSTA)
Category
Healthcare
Operating Margin for Lisata Therapeutics, Inc. (LSTA)
Operating Margin as of November 2026 TTM: -16,427.00%
According to Lisata Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -16,427.00%. At the end of 2025 the company had an operating margin of -10,711.18%.
Operating Margin history for Lisata Therapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -16,427.00% | 53.36% |
| 2025 | -10,711.18% | 377.99% |
| 2024 | -2,240.90% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | -100.00% |
| 2016 | -88.81% | -61.28% |
| 2015 | -229.35% | -28.74% |
| 2014 | -321.87% | 28.27% |
| 2013 | -250.93% | 18.34% |
| 2012 | -212.04% | -37.33% |
| 2011 | -338.36% | 1,151.33% |
| 2010 | -27.04% | -87.91% |
| 2009 | -223.68% | -97.98% |
| 2008 | -11,052.60% | 145.29% |
| 2007 | -4,506.02% | -56.08% |
| 2006 | -10,259.38% | 125.98% |
| 2005 | -4,540.05% | 49.54% |
| 2004 | -3,035.95% | 119.40% |
| 2003 | -1,383.72% | -2.06% |
| 2002 | -1,412.78% | -5.48% |
| 2001 | -1,494.69% | 215.78% |
| 2000 | -473.34% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Lisata Therapeutics, Inc.'s operating margin
What is Lisata Therapeutics, Inc.'s operating margin?
Lisata Therapeutics, Inc.'s operating margin is -16,427.00%, as of Nov 2026.
What was Lisata Therapeutics, Inc.'s operating margin in 2025?
In 2025, Lisata Therapeutics, Inc.'s operating margin was -10,711.18%, compared with -2,240.90% in 2024.
How has Lisata Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Lisata Therapeutics, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2025 (-10,711.18%).
How does Lisata Therapeutics, Inc.'s operating margin compare with similar companies?
Lisata Therapeutics, Inc.'s operating margin (-16,427.00%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.